Sunday, December 05, 2021

NEWS

Phase II of anti-Covid-19 trial for convalescents began in Cuba

Vacunas cubanas Abdala y Mambisa

Phase II of anti-Covid-19 trial for convalescents began in Cuba

Havana, nov 3 (Prensa Latina) Clinical trial Phase II with 'Abdala' and vaccine candidate 'Mambisa' for convalescents from Covid-19 in Cuba began here today, and included allergic people to thiomersal.
Share on facebook
Share on twitter
Share on whatsapp
Share on telegram
Share on email

The Center for Genetic Engineering and Biotechnology (CIGB), developer of both drugs, said on Twitter that Hermanos Ameijeiras Hospital in this capital, just like in phase I, hosts the new research.

They specified in the same post that at the end of the study, volunteers between 19 and 80 years of age who did not have any drug before or after convalescence will get results of the immune response to natural infection and booster doses.

‘Mambisa’, administered with nasal spray, drop dispenser or a Cuban device with a syringe, is a unique formulation based on the platform of recombinantly- produced antigens, technology with high safety, according to official information.

‘Abdala’, in turn, is the first vaccine against Covid-19 on the island and in Latin America, showing in its phase III trial with three doses, an efficacy of 100 percent to prevent serious conditions and death, and 92.28 percent against symptomatic disease.

On the other hand, 120 individuals from the same group took part last July in phase I of the clinical trial for convalescents with the same drugs.

Prior to this clinical trial, the country began another with the then vaccine candidate ‘Soberana Plus’, from the Finlay Vaccine Institute, which also sought to assess safety, reactogenicity and immunogenicity of a dose in patients recovered from the disease.

Participants, in the same age group, had a history of mild or moderate Covid-19, and of asymptomatic infection. In this phase I clinical trial with Soberana Plus, the drug proved the ability to induce high rates of neutralizing antibodies in convalescent patients.

ef/lcr/mem/nmr

RELATED
ÚLTIMO MINUTO
name of Prensa Latina

| Text SMS to 8100 with content PL
Receive 4 mesages x 25 cup

© 2016-2021 Prensa Latina
Latin American News Agency

Radio – Publications  – Videos – News by the minute.
All Rigts Reserved.

St. E No 454 , Vedado,  Habana, Cuba.
Phones: (+53) 7 838 3496, (+53) 7 838 3497, (+53) 7 838 3498, (+53) 7 838 3499
Prensa Latina © 2021 .

Web Site developed by IT Division  Prensa Latina.